Feride Uysal
Feride Uysal has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Elif Küçük
Department of Psychiatry, Faculty of Medicine, Yüksek İhtisas University, 06530 Ankara, Türkiye
5 shared publications - Özgür Özkalaycı
UNIVERSITY OF HEALTH SCIENCES, İSTANBUL BAĞCILAR HEALTH RESEARCH CENTER
3 shared publications - Deniz Güven
Department of Pediatrics, Etlik City Hospital, Ankara, Türkiye
2 shared publications - Ibrahim Kandemir
Department of Pediatrics, Istanbul Health and Technology University, Istanbul 34275, Turkey
2 shared publications - Mehmet Tolga Köle
Ankara Etlik Şehir Hastanesi
2 shared publications - Merih Altıntaş
İstanbul Erenköy Training and Research Hospital for Psychiatry and Neurological Diseases , İstanbul , Türkiye
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8677
Postpartum Depressive Symptoms and Mother–Infant Bonding at 4–24 Weeks Postpartum: A Cross-Sectional Study of Psychosocial and Breastfeeding-Related Factors
Background/Objectives: Postpartum depressive symptoms have been associated with maternal functioning and mother–infant bonding (MIB). This study primarily examined the association between postpartum depressive symptom severity and MIB, estimated the proportion screening positive for probable postpartum depression (PPD), and explored relevant sociodemographic and psychosocial correlates. Methods: In this cross-sectional study, 212 mothers assessed at 4–24 weeks postpartum during April–June 2025 completed the Edinburgh Postnatal Depression Scale (EPDS) and Maternal Attachment Inventory (MAI). The primary adjusted analysis used linear regression with HC3 robust standard errors, including infant age and selected clinical and psychosocial covariates. Because 39.2% of MAI scores were at the maximum, Tobit, fractional-logit, and ordinal regressions were used as complementary sensitivity analyses, alongside exploratory spline assessments. Results: Forty-one mothers (19.3%) screened positive for probable PPD (EPDS ≥13). Each 1-point higher EPDS score was associated with a 0.20-point lower MAI score (95% CI: −0.26 to −0.15), approximately one MAI point per five EPDS points. Observed-scale estimates were similar across linear, Tobit, and fractional-logit models, although exploratory splines suggested possible nonlinearity at sparsely represented EPDS extremes. In exploratory adjusted analyses, stressful breastfeeding and nonbreastfeeding were associated with higher EPDS scores. Separately, only four of 69 unadjusted exploratory comparisons survived false-discovery-rate correction, all involving probable PPD screening status and breastfeeding or spousal support. Conclusions: Greater depressive symptom severity was associated with lower bonding scores, but the absolute difference was small and its clinical significance uncertain. The cross-sectional design precludes causal inference.
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8677
Open AccessPostpartum Depressive Symptoms and Mother–Infant Bonding at 4–24 Weeks Postpartum: A Cross-Sectional Study of Psychosocial and Breastfeeding-Related Factors
Background/Objectives: Postpartum depressive symptoms have been associated with maternal functioning and mother–infant bonding (MIB). This study primarily examined the association between postpartum depressive symptom severity and MIB, estimated the proportion screening positive for probable postpartum depression (PPD), and explored relevant sociodemographic and psychosocial correlates. Methods: In this cross-sectional study, 212 mothers assessed at 4–24 weeks postpartum during April–June 2025 completed the Edinburgh Postnatal Depression Scale (EPDS) and Maternal Attachment Inventory (MAI). The primary adjusted analysis used linear regression with HC3 robust standard errors, including infant age and selected clinical and psychosocial covariates. Because 39.2% of MAI scores were at the maximum, Tobit, fractional-logit, and ordinal regressions were used as complementary sensitivity analyses, alongside exploratory spline assessments. Results: Forty-one mothers (19.3%) screened positive for probable PPD (EPDS ≥13). Each 1-point higher EPDS score was associated with a 0.20-point lower MAI score (95% CI: −0.26 to −0.15), approximately one MAI point per five EPDS points. Observed-scale estimates were similar across linear, Tobit, and fractional-logit models, although exploratory splines suggested possible nonlinearity at sparsely represented EPDS extremes. In exploratory adjusted analyses, stressful breastfeeding and nonbreastfeeding were associated with higher EPDS scores. Separately, only four of 69 unadjusted exploratory comparisons survived false-discovery-rate correction, all involving probable PPD screening status and breastfeeding or spousal support. Conclusions: Greater depressive symptom severity was associated with lower bonding scores, but the absolute difference was small and its clinical significance uncertain. The cross-sectional design precludes causal inference.
- Open Access
- 15 October 2026
- Published by Elsevier in Acta Psychologica
- Vol. 270
The interplay of anxiety and self-esteem in quality of life among patients with a stoma
- 15 October 2026
- Published by Elsevier in Acta Psychologica
- Vol. 270
Open AccessThe interplay of anxiety and self-esteem in quality of life among patients with a stoma
- Open Access
- 13 August 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (4) , 1264-1273
Vitamin D deficiency, depression severity, and suicide risk: evidence from patients with major depressive disorder
Background/aim: Major depressive disorder (MDD) is a common psychiatric condition characterized by depressive symptoms and suicide-related clinical features. Vitamin D status has been investigated as a potential clinical correlate of depression and suicidal ideation, but the direction and specificity of these associations remain uncertain. This cross-sectional study aimed to examine the associations among serum 25-hydroxyvitamin D [25(OH)D] levels, depressive symptom severity, suicidal ideation, and suicide-related cognitive–affective dimensions in adults diagnosed with MDD. Materials and methods: This cross-sectional study included 97 adults aged 18–65 years who were diagnosed with MDD according to DSM-5 criteria. Depressive symptom severity and suicide-related outcomes were assessed using the Hamilton Depression Rating Scale (HDRS), Suicidal Ideation Scale (SIS), and Suicide Probability Scale (SPS). Vitamin D status was classified as deficient (<20 ng/ mL), insufficient (20–29 ng/mL), or sufficient (≥30 ng/mL). Associations were examined using multivariable generalized linear models adjusted for available sociodemographic and clinical covariates. Results: Vitamin D deficiency was observed in 61.9% of participants and the mean serum 25(OH)D level was 18.4 ± 11.9 ng/mL. Lower serum 25(OH)D levels were significantly associated with higher HDRS, SIS, and SPS total/subscale scores. In adjusted models, higher serum 25(OH)D levels remained inversely associated with HDRS scores, SIS scores, and total SPS scores. Parental status was also associated with lower SIS scores, while a history of suicide attempts was associated with higher SPS–Suicidal Ideation scores. Conclusion: Lower serum 25(OH)D levels were associated with greater depressive symptom severity and higher suicide-related scale scores in adults with MDD, particularly across cognitive–affective domains relevant to suicide probability. However, given the study’s cross-sectional single-center design, absence of a healthy control group, modest sample size, and adjustment limited to available covariates, these findings should be interpreted as associations rather than evidence of causality, directionality, or established biomarker utility.
- 13 August 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (4) , 1264-1273
Open AccessVitamin D deficiency, depression severity, and suicide risk: evidence from patients with major depressive disorder
Background/aim: Major depressive disorder (MDD) is a common psychiatric condition characterized by depressive symptoms and suicide-related clinical features. Vitamin D status has been investigated as a potential clinical correlate of depression and suicidal ideation, but the direction and specificity of these associations remain uncertain. This cross-sectional study aimed to examine the associations among serum 25-hydroxyvitamin D [25(OH)D] levels, depressive symptom severity, suicidal ideation, and suicide-related cognitive–affective dimensions in adults diagnosed with MDD. Materials and methods: This cross-sectional study included 97 adults aged 18–65 years who were diagnosed with MDD according to DSM-5 criteria. Depressive symptom severity and suicide-related outcomes were assessed using the Hamilton Depression Rating Scale (HDRS), Suicidal Ideation Scale (SIS), and Suicide Probability Scale (SPS). Vitamin D status was classified as deficient (<20 ng/ mL), insufficient (20–29 ng/mL), or sufficient (≥30 ng/mL). Associations were examined using multivariable generalized linear models adjusted for available sociodemographic and clinical covariates. Results: Vitamin D deficiency was observed in 61.9% of participants and the mean serum 25(OH)D level was 18.4 ± 11.9 ng/mL. Lower serum 25(OH)D levels were significantly associated with higher HDRS, SIS, and SPS total/subscale scores. In adjusted models, higher serum 25(OH)D levels remained inversely associated with HDRS scores, SIS scores, and total SPS scores. Parental status was also associated with lower SIS scores, while a history of suicide attempts was associated with higher SPS–Suicidal Ideation scores. Conclusion: Lower serum 25(OH)D levels were associated with greater depressive symptom severity and higher suicide-related scale scores in adults with MDD, particularly across cognitive–affective domains relevant to suicide probability. However, given the study’s cross-sectional single-center design, absence of a healthy control group, modest sample size, and adjustment limited to available covariates, these findings should be interpreted as associations rather than evidence of causality, directionality, or established biomarker utility.
- Open Access
- 21 April 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Antipsychotic dose is not associated with cognitive function in patients with schizophrenia aged under 40: a cross-sectional observational study with retrospective dose estimation
This study aimed to examine the relationship between antipsychotic dosage and cognitive performance in young patients with schizophrenia. A relatively homogeneous sample was selected to reduce clinical heterogeneity and improve sample comparability. In this cross-sectional observational study, psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive performance was evaluated with the Montreal Cognitive Assessment (MoCA) in clinically stable patients with schizophrenia under the age of 40 who were followed at a Community Mental Health Center. Total antipsychotic dose was calculated using olanzapine equivalents, and 1-year cumulative exposure was estimated using the mg×day formula. Both frequentist and Bayesian analytical approaches were applied. No significant correlations were found between either daily or cumulative antipsychotic doses and MoCA scores (r = 0.067; p = 0.675; BF₁₀ = 0.260; and r = 0.028; p = 0.864; BF₁₀ = 0.554, respectively). Longer illness duration and higher scores on all PANSS subscales were associated with lower MoCA scores, whereas longer education and older age at diagnosis were positively correlated with cognitive performance. Although prior research has suggested dose-related cognitive impairment, our findings did not provide evidence supporting this association in young, well-characterised patients within the constraints of a cross-sectional observational design. These results indicate that effective therapeutic dosing can be pursued with appropriate clinical monitoring, while acknowledging that potential cognitive effects should still be taken into consideration. The online version contains supplementary material available at 10.1186/s12888-026-08086-x. The online version contains supplementary material available at 10.1186/s12888-026-08086-x.
- 21 April 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessAntipsychotic dose is not associated with cognitive function in patients with schizophrenia aged under 40: a cross-sectional observational study with retrospective dose estimation
This study aimed to examine the relationship between antipsychotic dosage and cognitive performance in young patients with schizophrenia. A relatively homogeneous sample was selected to reduce clinical heterogeneity and improve sample comparability. In this cross-sectional observational study, psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive performance was evaluated with the Montreal Cognitive Assessment (MoCA) in clinically stable patients with schizophrenia under the age of 40 who were followed at a Community Mental Health Center. Total antipsychotic dose was calculated using olanzapine equivalents, and 1-year cumulative exposure was estimated using the mg×day formula. Both frequentist and Bayesian analytical approaches were applied. No significant correlations were found between either daily or cumulative antipsychotic doses and MoCA scores (r = 0.067; p = 0.675; BF₁₀ = 0.260; and r = 0.028; p = 0.864; BF₁₀ = 0.554, respectively). Longer illness duration and higher scores on all PANSS subscales were associated with lower MoCA scores, whereas longer education and older age at diagnosis were positively correlated with cognitive performance. Although prior research has suggested dose-related cognitive impairment, our findings did not provide evidence supporting this association in young, well-characterised patients within the constraints of a cross-sectional observational design. These results indicate that effective therapeutic dosing can be pursued with appropriate clinical monitoring, while acknowledging that potential cognitive effects should still be taken into consideration. The online version contains supplementary material available at 10.1186/s12888-026-08086-x. The online version contains supplementary material available at 10.1186/s12888-026-08086-x.
- Open Access
- 6 March 2026
- Published by Elsevier in Acta Psychologica
- Vol. 264, 106611
Anxiety levels and associated sociodemographic factors in mothers of children with first febrile seizures: A case-control study
- 6 March 2026
- Published by Elsevier in Acta Psychologica
- Vol. 264, 106611
Open AccessAnxiety levels and associated sociodemographic factors in mothers of children with first febrile seizures: A case-control study